Assessing Patient Risk, Benefit, and Outcomes in Drug Development: Insights From Afatinib Clinical Trials Across Diverse Cancer Indications

In 2013, afatinib was approved for non–small-cell lung cancer with subsequent indication expansion. We investigated published afatinib clinical trials to assess risk and benefit profiles for the drug in its approved indication of non–small-cell lung cancer as well as in off-label uses. Previous lite...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Clinical therapeutics 2024-06, Vol.46 (6), p.e107-e113
Hauptverfasser:	Hunter Hall, Rafe, Wright, Carson L., Hughes, Griffin K., Peña, Andriana M., Ladd, Chase, Gardner, Brooke, McIntire, Ryan, Ferrell, Matt, Rubenstein, Jane, Tuia, Jordan, Haslam, Alyson, Prasad, Vinay, Vassar, Matt
Format:	Artikel
Sprache:	eng
Schlagworte:	Adverse events Afatinib Breast cancer Breast carcinoma Cancer therapies Clinical trials ClinicalTrials.gov Cross-sectional study Drug development Drug dosages Effectiveness FDA approval Head & neck cancer Head and neck carcinoma Indication Labels Lung cancer Patient safety Patients Pharmaceutical industry Response rates Risk analysis Risk assessment Small cell lung carcinoma Squamous cell carcinoma Statistical analysis Toxicity Tumors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!